Ashwini Shewade

Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study

Carla Casulo, Melissa C. Larson, Julianne J. Lunde et al. · The Lancet Haematology · 2022 · 60 citations · Full text

Lymphoid Neoplasia, Oncology, Systemic Treatment +5

Comparative effectiveness and safety of rituximab versus subsequent anti–tumor necrosis factor therapy in patients with rheumatoid arthritis with prior exposure to anti–tumor necrosis factor therapies in the United States Corrona registry

Leslie R. Harrold, George Reed, Robert Magner et al. · Arthritis Research & Therapy · 2015 · 53 citations · Full text

Necrosis Factor Therapies, Rheumatology, Rheumatoid Disorder +9

Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia

John Hornberger, Carolina Reyes, Ashwini Shewade et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2011 · 30 citations

Lifetime Horizon, Hematological Malignancy, Lymphoid Neoplasia +14

Effectiveness of Rituximab for the Treatment of Rheumatoid Arthritis in Patients with Prior Exposure to Anti-TNF: Results from the CORRONA Registry

Leslie R. Harrold, George Reed, Ashwini Shewade et al. · The Journal of Rheumatology · 2015 · 26 citations · Full text

Immunology, Pharmacotherapy, Psoriatic Arthritis +16

Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy

John Hornberger, R. Chien, Mark Friedmann et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2012 · 23 citations